YBGJ (Yubo International Biotech) Quick Ratio: 0.19 (As of Mar. 2026) — Near Median


What is Yubo International Biotech Quick Ratio?

Yubo International Biotech YBGJ Quick Ratio is 0.19 as of Mar. 2026, which is at its 10-year median of 0.19. The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Yubo International Biotech ranks worse than 96.6% on this metric.

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Yubo International Biotech's quick ratio for the quarter that ended in Mar. 2026 was 0.19.

Yubo International Biotech has a quick ratio of 0.19. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Yubo International Biotech's Quick Ratio or its related term are showing as below:

YBGJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.12   Med: 0.19   Max: 1.44
Current: 0.19

During the past 6 years, Yubo International Biotech's highest Quick Ratio was 1.44. The lowest was 0.12. And the median was 0.19.

YBGJ's Quick Ratio is ranked worse than
96.6% of 854 companies
in the Medical Devices & Instruments industry
Industry Median: 1.885 vs YBGJ: 0.19

Yubo International Biotech  (OTCPK:YBGJ) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Yubo International Biotech Quick Ratio Related Terms


Yubo International Biotech Quick Ratio Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech Quick Ratio Chart

Yubo International Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Quick Ratio
Get a 7-Day Free Trial 0.32 0.17 0.15 0.14 0.23

Yubo International Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.12 0.24 0.23 0.19

YBGJ vs GCTK, ECIA, RSCF: Quick Ratio Comparison

For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yubo International Biotech Quick Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Yubo International Biotech's Quick Ratio falls into.



Yubo International Biotech Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Yubo International Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Quick Ratio (A: Dec. 2025 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.668-0.024)/2.791
=0.23

Yubo International Biotech's Quick Ratio for the quarter that ended in Mar. 2026 is calculated as

Quick Ratio (Q: Mar. 2026 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.598-0.024)/3.019
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Quick Ratio →
What does a Quick Ratio of 0.19 mean?
Yubo International Biotech (YBGJ) has a Quick Ratio of 0.19 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Yubo International Biotech and its competitors. This is near median its historical median of 0.19. Over the past decade, Yubo International Biotech's Quick Ratio has ranged from 0.12 to 1.44. According to the industry distribution chart, Yubo International Biotech ranks #825 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 96.6%.
Is Yubo International Biotech's Quick Ratio too high?
Yubo International Biotech's current Quick Ratio of 0.19 is near median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 1.44. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Yubo International Biotech's value of 0.19 is 89.9% below this industry median. Based on the distribution chart, Yubo International Biotech ranks #825 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Yubo International Biotech's Quick Ratio compare to GCTK and ECIA?
According to the Medical Devices & Instruments industry distribution chart, Yubo International Biotech ranks #825 out of 854 companies for Quick Ratio. This places Yubo International Biotech in the lower half of its industry. The industry median Quick Ratio is 1.89. Yubo International Biotech's value of 0.19 is 89.9% below this benchmark. Historically, Yubo International Biotech's own Quick Ratio has ranged from 0.12 to 1.44 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 1.89, Yubo International Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Yubo International Biotech's current Quick Ratio of 0.19 is 89.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Yubo International Biotech and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yubo International Biotech's current Quick Ratio is 0.19, which is near median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yubo International Biotech stock overvalued right now?
Yubo International Biotech (YBGJ) has a current Quick Ratio of 0.19. The current Quick Ratio is 0.19, which is near median its 10-year median of 0.19 and 89.9% below the Medical Devices & Instruments industry median of 1.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current Quick Ratio is 0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026
Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.